{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:30:36Z","timestamp":1761895836222},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T00:00:00Z","timestamp":1394409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T00:00:00Z","timestamp":1394409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1038\/bmt.2014.35","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T14:43:59Z","timestamp":1394462639000},"page":"843-844","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT"],"prefix":"10.1038","volume":"49","author":[{"given":"S E","family":"Langabeer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S L","family":"McCarron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M T","family":"O'Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Conneally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,10]]},"reference":[{"key":"BFbmt201435_CR1","first-page":"80","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"JW Vardiman","year":"2008","unstructured":"Vardiman JW, Bennett JM, Bain BJ, Brunning RD, Thiele J . Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues . International Agency for Research on Cancer: Lyon, France, 2008, pp 80\u201381."},{"key":"BFbmt201435_CR2","first-page":"1566","volume":"91","author":"M Breccia","year":"2006","unstructured":"Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G . Identification of risk factors in atypical chronic myeloid leukemia. Haematologica 2006; 91: 1566\u20131568.","journal-title":"Haematologica"},{"key":"BFbmt201435_CR3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/sj.bmt.1704686","volume":"34","author":"M Koldehoff","year":"2004","unstructured":"Koldehoff M, Beelen DW, Trenschel R, Steckel NK, Peceny R, Ditschkowski M et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant 2004; 34: 1047\u20131050.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201435_CR4","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","volume":"368","author":"JE Maxson","year":"2013","unstructured":"Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368: 1781\u20131790.","journal-title":"N Engl J Med"},{"key":"BFbmt201435_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ng.2495","volume":"45","author":"R Piazza","year":"2013","unstructured":"Piazza R, Valletta S, Winkelman N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18\u201324.","journal-title":"Nat Genet"},{"key":"BFbmt201435_CR6","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/leu.2013.122","volume":"27","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson CA et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27: 1870\u20131873.","journal-title":"Leukemia"},{"key":"BFbmt201435_CR7","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/bmt.2009.367","volume":"45","author":"H Alchalby","year":"2010","unstructured":"Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant 2010; 45: 1404\u20131407.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201435_CR8","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","volume":"116","author":"H Alchalby","year":"2010","unstructured":"Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2 V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572\u20133581.","journal-title":"Blood"},{"key":"BFbmt201435_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3324\/haematol.2012.076901","volume":"98","author":"T Lange","year":"2013","unstructured":"Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, J\u00e4kel N et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica 2013; 98: 722\u2013728.","journal-title":"Haematologica"},{"key":"BFbmt201435_CR10","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","volume":"113","author":"N Kr\u00f6ger","year":"2009","unstructured":"Kr\u00f6ger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F et al. JAK2 V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009; 113: 1866\u20131868.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201435","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:24:37Z","timestamp":1648059877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,10]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["BFbmt201435"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2014.35","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,10]]},"assertion":[{"value":"10 March 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}